For the quarter ending 2025-09-30, ADPT had $11,840K increase in cash & cash equivalents over the period. -$7,536K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 9,545 | -55,423 |
| Depreciation expense | 3,977 | 8,391 |
| Noncash lease expense | 1,350 | 2,642 |
| Share-based compensation expense | 13,257 | 25,506 |
| Intangible assets amortization | 428 | 842 |
| Investment amortization | 516 | 1,708 |
| Impairment of long-lived assets | 0 | - |
| Inventory reserve | -6 | -46 |
| Noncash interest expense | -1,728 | 287 |
| Other | -434 | -43 |
| Accounts receivable, net | 536 | 2,566 |
| Inventory | 1,347 | -359 |
| Prepaid expenses and other current assets | 2,524 | 8 |
| Accounts payable and accrued liabilities | 5,896 | -6,396 |
| Operating lease right-of-use assets and liabilities | -2,567 | -5,230 |
| Deferred revenue | -32,790 | -7,612 |
| Other | 0 | -5 |
| Net cash used in operating activities | -7,127 | -40,914 |
| Purchases of property and equipment | 409 | 1,914 |
| Purchases of marketable securities | 33,191 | 101,792 |
| Proceeds from maturities of marketable securities | 50,883 | 132,625 |
| Net cash provided by investing activities | 17,283 | 28,919 |
| Proceeds from exercise of stock options | 1,684 | 7,061 |
| Net cash provided by financing activities | 1,684 | 7,061 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,840 | -4,934 |
| Cash and cash equivalents at beginning of period | 50,817 | - |
| Cash and cash equivalents at end of period | 57,723 | - |
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)